Showing results (61-70 of 93) with videos related to
Sort By:
Pageof 10
Journal of Cellular Physiology|August 19, 2010
Myeloid-specific GPCR kinase-2 negatively regulates NF-κB1p105-ERK pathway and limits endotoxemic shock in miceSonika Patial, Yogesh Saini, Sitaram Parvataneni, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 30, 2012
Vaccines expressing the innate immune modulator EAT-2 elicit potent effector memory T lymphocyte responses despite pre-existing vaccine immunityYasser Ali Aldhamen, Sergey S Seregin, Nathaniel J Schuldt, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type IIBaodong Sun, Haoyue Zhang, Luis M Franco, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 29, 2006
APOE epsilon3 gene transfer attenuates brain damage after experimental strokeBarry W McColl, Ailsa L McGregor, Andrew Wong, et al.Annals of Neurology|March 29, 2002
Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neuronsSumeer Dhar, Rhonda L Bitting, Svetlana N Rylova, et al.Vaccine|May 7, 2016
CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targetsYasser A Aldhamen, David P W Rastall, Weimin Chen, et al.Molecular Therapy Oncolytics|January 17, 2022
Adenoviral delivery of an immunomodulatory protein to the tumor microenvironment controls tumor growthPatrick O'Connell, Maja K Blake, Yuliya Pepelyayeva, et al.Plos One|July 16, 2011
TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivoSergey S Seregin, Yasser A Aldhamen, Daniel M Appledorn, et al.Cancer Research|February 7, 2002
The CLN3 gene is a novel molecular target for cancer drug discoverySvetlana N Rylova, Andrea Amalfitano, Dixie-Ann Persaud-Sawin, et al.Molecular Genetics and Metabolism|February 28, 2012
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cellsSuhrad G Banugaria, Trusha T Patel, Joanne Mackey, et al.Pageof 10